Findings

What do systematic reviews say?

10 questions · 16 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 10 · 62.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 12.5%High 4 · 25%

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma

The review found no eligible studies for this question.

1 finding from 1 review

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dinutuximab‐containing immunotherapy vs usual care

Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rapid COJEC vs standard induction therapies

Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma

The review found no eligible studies for this question.

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neuronavigation image‐guided surgery vs surgery

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

2 findings from 2 reviews · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

iMRI image‐guided surgery vs surgery

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

2 findings from 2 reviews · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

5‐ALA image‐guided surgery vs surgery

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

2 findings from 2 reviews · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma

The intervention showed no clear difference in progression‐free survival (high certainty).

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
HR 1.34 [0.81, 2.2]
1 study · 83 participants
High

Intervention not reported

Progression‐free survival · Adult patients with follicular lymphoma

The intervention probably leads to lower progression‐free survival (moderate certainty).

1 finding from 1 review

High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
HR 0.42 [0.33, 0.54]
3 studies · 540 participants
Moderate

Anti‐angiogenic therapy vs no anti‐angiogenic therapy

Progression‐free survival · people with HGG

Anti‐angiogenic therapy leads to lower progression‐free survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.73 [0.68, 0.79]
10 studies · 3595 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.75 [0.69, 0.82]
8 studies · 2833 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.64 [0.54, 0.76]
2 studies · 762 participants
Moderate

Show 1 more finding

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.72 [0.66, 0.77]
10 studies · 3464 participants
High